Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 February 2025 | Story Martinette Brits | Photo Supplied
Prof Maxim Finkelstein, A1-rated researcher from the University of the Free State, has been selected as the 2024 - 2026 Ewha Global Fellow by Ewha Womans University.

An esteemed researcher from the University of the Free State (UFS), Prof Maxim Finkelstein, has been named a 2024 - 2026 Ewha Global Fellow (EGF) by Ewha Womans University in South Korea.

Prof Finkelstein, an A1-rated researcher from the Department of Mathematical Statistics and Actuarial Science, received this honour in recognition of his outstanding collaboration with Prof Ji Hwan Cha from Ewha’s Department of Statistics. Prof Cha nominated him as a leading expert in his field, highlighting their long-standing partnership and significant contributions to mathematical sciences.

According to Hyang-Sook Lee, President of the Ewha Womans University, the EGF programme “encourages distinguished scholars from all over the world to actively collaborate in research and education with Ewha faculty members.”

 

The genesis of a unique collaboration

Prof Finkelstein has collaborated extensively with researchers across Europe and the United States but his partnership with Prof Cha is particularly notable. “I started working at the UFS as a Professor in 1998 when he had just obtained his PhD,” recalls Prof Finkelstein.

At the time, Prof Finkelstein was already an established researcher, while Prof Cha was in the early stages. “His letter to me about one of my articles was sent to me by regular mail to my previous working address in Saint Petersburg, Russia, and did not reach me. We eventually connected around 2006, and our collaboration gradually took shape,” he explains.

Over the years, their partnership evolved into a balanced and mutually enriching research relationship. Their joint efforts have resulted in over 120 published papers and two books, setting new standards in the Mathematical Theory of Reliability and its applications. This collaboration has significantly influenced both their careers and contributed to Prof Finkelstein’s recognition with South Africa’s highest research accolades, including an NRF A1 rating in "Mathematical Sciences" in 2021, following his A2 rating in 2015.

 

A breakthrough in stochastic modelling

One of the major achievements of Prof Finkelstein's collaboration with Ewha has been their pioneering work in stochastic modelling. Their research led to the development of the Generalised Polya Process, a novel model for understanding natural and industrial point events - such as failures in electricity generation, lightning strikes, and hurricanes. By incorporating the ‘history’ of previous events, this model offers a more precise stochastic description of real-world phenomena.

The results of their research have been widely published and have paved the way for further exploration into more complex stochastic processes. Some of their key findings were summarised in the 2018 Springer book Point Processes for Reliability Analysis.

 

Looking ahead: Future collaboration and continued innovation

Despite being in the later years of his career, Prof Finkelstein remains deeply engaged in research and committed to his partnership with Ewha. Due to the challenges posed by the COVID-19 pandemic, his visits to Ewha were limited, but plans are now in place for future visits. During these visits, he will deliver lectures to students and collaborate with faculty members.

For Prof Finkelstein, continuing his nearly two-decade-long collaboration with Prof Cha remains a vital and exciting part of his academic journey. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept